Notably, some resistant breast cancer patients lack mutations in the PI3K/AKT/mTOR pathway, indicating that nongenetic reprofiling and hyperactivation of the PI3K/AKT/mTOR pathway play significant roles [61]. This evidence concerns the gene AKT1 and breast cancer.